{"filings":[{"id":2548157,"accession_number":"0001099800-26-000048","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2026-08-28T20:15:18+00:00","items":["5.02"],"status":"ready","headline":"Edwards Lifesciences Strategy VP Donald Bobo to retire by mid-2027; successor search begins","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald E. Bobo, Jr., Corporate Vice President of Strategy and Corporate Development, plans to retire by mid-year 2027.","Board will begin a selection process promptly to identify a successor, with transition expected during 2027.","Bobo is expected to remain as a consultant with the Company through the end of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1830398,"accession_number":"0001099800-26-000038","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2026-07-23T20:29:00+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q2 sales up 13.6% to $1.74B; raises full-year sales and TAVR guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $1.74B (+13.6% YoY); adjusted EPS $0.78; gross margin 77.5%.","TAVR sales $1.26B (+11.3% YoY); TMTT sales $195.9M (+47.3% YoY); Surgical $284M (+6.5% YoY).","Raised FY constant currency sales growth guidance to 10-11% (from 9-11%); TAVR growth to 8-9% (from 7-9%).","Reaffirmed adjusted EPS guidance $2.95-$3.05; Q3 guidance: sales $1.63-$1.71B, adj EPS $0.71-$0.77.","Cash $2.9B, debt $600M; $1.5B remaining share repurchase authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91300,"accession_number":"0001099800-26-000028","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edwards shareholders approve 7M share increase in Long-Term Stock Program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders authorized 7M additional shares, raising total available to 341.5M under the amended program.","All 9 director nominees reelected; proposal received between 428M and 474M For votes each.","Advisory vote on named executive officer compensation passed with ~89% of votes cast.","Ratification of PwC as independent auditor for FY2026 approved with ~89% of votes cast.","Stock program amendment (Proposal 4) passed with 456.7M For (96% of votes cast, excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91299,"accession_number":"0001099800-26-000023","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Edwards Lifesciences appoints Theodora Mistras as CFO, effective May 29, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Theodora Mistras appointed CFO effective May 29, 2026, succeeding Scott Ullem (announced October transition).","Compensation: $925K base salary, $2.013M sign-on bonus (pro-rata clawback within 24 months), $8M RSUs (vesting over 3 years).","Mistras was previously CFO of Viatris (since March 2024) and held senior roles at Citigroup and Goldman Sachs in healthcare IB.","She is eligible for severance of at least 1x base salary plus 1x target bonus, pro-rated bonus, and $50K outplacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91298,"accession_number":"0001099800-26-000021","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q1 sales +16.7% to $1.65B; raises FY guidance on TAVR strength","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $1.65B, +16.7% YoY; constant currency +12.7%; TAVR sales $1.20B, +14.4%.","GAAP EPS $0.66; adjusted EPS $0.78, beating consensus; gross margin 78.0%.","Raises FY 2026 constant currency sales growth guidance to 9-11% (from 8-10%); new TAVR growth 7-9%.","Raises FY adjusted EPS guidance to $2.95-$3.05 from $2.90-$3.05; sees Q2 sales $1.66-$1.74B.","Completed $500M ASR; $1.5B remaining buyback authorization; cash $2.4B, debt $0.6B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1648600000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101288,"accession_number":"0001099800-26-000006","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q4 sales $1.57B (+13.3%), TAVR +12%, TMTT >40% growth; FY2026 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.11, adjusted EPS $0.58; gross margin 78.1% (78.3% adjusted).","TAVR sales $1.16B (+12.0%); TMTT sales $156M (+40%). Full-year sales growth 11.5%.","FY2026 outlook: constant-currency sales growth 8–10%, adjusted EPS $2.90–$3.05.","FDA approved SAPIEN M3, first transcatheter mitral replacement; CMS opened TAVR NCD reconsideration.","Q1 2026 guidance: sales $1.55–$1.63B, adjusted EPS $0.70–$0.76."],"consensus_eps_estimate":null,"consensus_eps_actual":1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":6067600000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101287,"accession_number":"0001099800-26-000002","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FTC injunction blocks Edwards' JenaValve acquisition; Edwards raises FY2026 EPS guidance to $2.90-$3.05","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["US District Court grants FTC motion for injunction blocking Edwards' acquisition of JenaValve; deal terminated.","Edwards revises FY2026 adjusted EPS guidance upward to $2.90-$3.05 from $2.80-$2.95.","Edwards disagrees with ruling, remains committed to AR therapy; advancing SOJOURN valve and JOURNEY trial.","Additional updates expected at Q4 earnings call in February."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117649,"accession_number":"0001193125-25-258662","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Edwards Lifesciences CFO Scott Ullem to step down by mid-2026; successor search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Scott Ullem informed company on Oct. 30, 2025 of decision to transition by mid-2026.","Company initiating selection process to appoint a new CFO; Ullem will serve in advisory role after appointment.","Plan described as a planned transition to ensure continuity and smooth handoff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117648,"accession_number":"0001099800-25-000059","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q3 sales rise 14.7% to $1.55B; raises FY EPS guidance to $2.56-$2.62","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $1.55B (+14.7% YoY); adjusted EPS $0.67 vs $0.50 GAAP.","TAVR sales $1.15B (+12.4%); TMTT sales $145.2M (+59.3%).","Raised FY2025 adjusted EPS guidance to $2.56-$2.62 from high end of $2.45-$2.55.","Raised TAVR sales growth guidance to 7-8% from 6-7%; total sales growth to high end of 9-10%.","Board increased share repurchase authorization to $2.1B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":4498000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134084,"accession_number":"0001099800-25-000056","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Edwards Lifesciences announces $500M accelerated share repurchase, initial ~5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$500M accelerated share repurchase executed; initial delivery of ~5 million shares.","Total 2025 share repurchases exceed $800 million; $600M remains under authorization.","Funded with existing cash; final share count based on VWAP during ASR term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134083,"accession_number":"0001099800-25-000046","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FTC moves to block Edwards' proposed JenaValve acquisition; Edwards raises FY2025 adjusted EPS guidance to $2.45-$2.55","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FTC moved to block Edwards' proposed acquisition of JenaValve Technology; Edwards disagrees and will continue pursuing regulatory approval.","Edwards estimates a final determination on the acquisition by end of Q1 2026.","Full-year 2025 adjusted EPS guidance raised to high-end of $2.45-$2.55 (from $2.40-$2.50); revenue guidance unchanged.","Minimal impact to Q3 2025 adjusted EPS guidance from FTC action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134082,"accession_number":"0001193125-25-164527","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Edwards Lifesciences EVP Larry Wood to resign; Daniel Lippis to lead TAVR business","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Larry Wood, Corporate VP and Group President of TAVR and Surgical Structural Heart, resigns effective Sept 1, 2025.","Wood departs to accept a senior leadership role at another company outside cardiovascular.","Daniel J. Lippis, current Corporate VP for Japan, Greater China, and Asia Pacific, will succeed as Corporate VP for TAVR.","The transition is effective September 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134081,"accession_number":"0001099800-25-000037","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q2 sales up 11.9% to $1.53B; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP EPS $0.57; adjusted EPS $0.67.","TAVR sales $1.1B (+8.9%); TMTT $134.5M (+61.9%); Surgical $267M (+7.7%).","Full-year sales growth guidance raised to 9-10% (from 8-10%); adjusted EPS expected at high end of $2.40-$2.50.","SAPIEN M3 CE Mark approved in Q2; 10-year PARTNER II data affirm durability.","Q3 guidance: sales $1.46-$1.54B, adjusted EPS $0.54-$0.60."],"consensus_eps_estimate":null,"consensus_eps_actual":1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":2944900000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150834,"accession_number":"0001099800-25-000026","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Edwards shareholders approve 5.66M new shares for employee stock purchase plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved US ESPP amendment adding 4.2M shares and International ESPP adding 1.46M shares.","All nine director nominees elected with strong support; lowest was Paul LaViolette at 92.3% for.","Advisory say-on-pay proposal passed with 88.0% of votes cast in favor.","Ratification of PwC as auditor for FY2025 approved with 89.9% for.","Broker non-votes present on all proposals except auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150833,"accession_number":"0001099800-25-000020","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q1 sales $1.41B (+6.2%), TMTT surging 58%, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $1.41B (+6.2% reported, +7.9% adjusted); GAAP EPS $0.62, adjusted EPS $0.64.","TAVR sales $1.05B (+3.8%, +5.4% constant currency); TMTT sales $115M (+58%).","Gross margin 78.7%; operating margin 27.9% (adj. 29.1%) on favorable mix and delayed expenses.","2025 guidance: total sales raised to $5.7-6.1B; TMTT raised to $530-550M; adj. EPS reaffirmed $2.40-2.50.","Q2 guidance: sales $1.45-1.53B, adj. EPS $0.59-0.65; CE Mark SAPIEN M3, NCD for EVOQUE."],"consensus_eps_estimate":null,"consensus_eps_actual":0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1412700000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169769,"accession_number":"0001099800-25-000003","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q4 sales $1.39B (+9%), adjusted EPS $0.59; reiterates 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $1.39B (+9% YoY); TAVR $1.04B (+6%), TMTT $105M (+88%).","GAAP EPS $0.58; adjusted EPS $0.59; full-year sales from continuing ops $5.5B.","2025 guidance reaffirmed: constant currency sales growth 8-10%, adjusted EPS $2.40-$2.50.","Expect mid-year FDA approval for asymptomatic TAVR; presented EARLY TAVR and TRISCEND II trials.","Cash $3.0B; debt $600M; adjusted gross margin 79.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":6.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":5439500000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186820,"accession_number":"0001099800-24-000084","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q3 sales up 9% to $1.33B; TAVR +6%, TMTT +73%; adjusted EPS $0.67 beats guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales from continuing ops $1.33B (+9% as-reported, +10% constant currency); adjusted EPS $0.67 ahead of July guidance.","TAVR sales $1.0B (+6% reported, +7% constant currency); TMTT sales $91M (+73%) driven by PASCAL and EVOQUE launches.","GAAP EPS $5.13 includes one-time gain from sale of Critical Care unit; adjusted gross margin 80.7% vs 79.9% last year.","Repurchased $1.0B of stock in Q3; remaining authorization $1.4B; cash $3.5B, debt $600M.","Reiterated FY2024 total sales growth 8-10%; Q4 guidance: sales $1.33-1.39B, EPS $0.53-0.57."],"consensus_eps_estimate":null,"consensus_eps_actual":6.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":4053700000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203359,"accession_number":"0001099800-24-000082","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Edwards completes $4.2B sale of Critical Care to BD, adds $1.5B buyback","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed all-cash sale of Critical Care to BD (NYSE: BDX) for $4.2B.","Board authorized additional $1.5B share repurchase; entered $500M accelerated repurchase.","Total $1B repurchased to date including prior $500M 10b5-1 and open-market buys.","Net proceeds to fund strategic initiatives, prior acquisitions, and share repurchases.","Company to discuss strategy and outlook at Wells Fargo Healthcare Conference on Sept 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203358,"accession_number":"0001099800-24-000069","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Edwards Q2 revenue +8% CC, TAVR guidance cut to 5-7%; announces $1.2B in acquisitions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 continuing ops sales $1.35B (+7% reported, +8% CC); adj. EPS $0.70, GAAP EPS $0.61.","TAVR sales $1.0B, growth 5% (6% CC); FY2024 TAVR guidance lowered to 5-7% from 8-10%.","TMTT sales $83M, +75%; FY2024 TMTT guidance raised to high end of $320-340M range.","Entered agreement to acquire JenaValve (aortic regurgitation) and exercised option to acquire Endotronix (PA pressure sensor); total upfront ~$1.2B cash plus up to $445M milestones.","Critical Care sale ($4.2B) on track to close late Q3 2024; Q3 sales guidance $1.56-1.64B, EPS $0.67-0.71."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203357,"accession_number":"0001099800-24-000066","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edwards Lifesciences exercises option to acquire Innovalve for ~$300M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Edwards Lifesciences (EW) acquires early-stage TMVR company Innovalve Bio Medical Ltd.","Consideration of ~$300M in cash; expected closing by end of 2024.","Innovalve to join TMTT product group; initial investment made in 2017.","Edwards' SAPIEN M3 TMVR system on track for European approval by end of 2025.","Acquisition aims to expand treatable mitral valve population with combined platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203356,"accession_number":"0001099800-24-000061","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Edwards Lifesciences appoints David T. Feinberg to Board, effective July 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David T. Feinberg, M.D. appointed to Edwards Lifesciences Board and Audit Committee, effective July 10, 2024.","Dr. Feinberg is Chairman of Oracle Health, former CEO of Cerner (acquired by Oracle in 2022).","Previously held leadership roles at Google Health, Geisinger Health, and UCLA Health.","Will receive standard non-employee director compensation per 2024 Proxy and standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219735,"accession_number":"0001099800-24-000054","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Edwards Lifesciences principal accounting officer Sellers retires; Dahl named successor effective July 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert W.A. Sellers, Senior VP and Principal Accounting Officer, retires effective July 1, 2024.","Andrew M. Dahl, currently Senior VP and Corporate Controller, succeeds Sellers as Principal Accounting Officer.","Dahl joined Edwards in February 2024; prior roles include VP at Medtronic and Manager at Deloitte.","No material interest, arrangement, or family relationship exists between Dahl and Edwards officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219734,"accession_number":"0001193125-24-152323","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edwards Lifesciences sells Critical Care unit to BD for $4.2B cash, ends spin-off","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash sale of Critical Care product group to BD (NYSE: BDX) valued at $4.2 billion.","Edwards will no longer pursue the previously announced spin-off of Critical Care.","Transaction expected to close by end of 2024; impact to 2024 adjusted EPS immaterial.","Critical Care will remain in Irvine, CA, led by current corporate VP Katie Szyman.","After-tax cash proceeds to fund strategic structural heart innovation investments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219733,"accession_number":"0001099800-24-000045","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Edwards Lifesciences annual meeting results: all four proposals approved by stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected with >447M 'for' votes each.","Advisory say-on-pay passed with 433M for vs 42M against.","Ratification of PwC as auditor for FY2024 approved (453M for, 53M against).","Amended long-term stock incentive compensation program approved (453M for, 21M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219732,"accession_number":"0001099800-24-000037","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q1 sales $1.6B (+10%), TMTT +75%; raises FY sales guidance to high end 8-10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $1.6B, up 10% reported and constant currency; GAAP EPS $0.58, adjusted EPS $0.66.","TAVR sales $1.0B (+6% reported, +8% constant currency adjusted for billing days).","TMTT sales $73M (+75%); EVOQUE received FDA approval for tricuspid regurgitation in Feb.","Full-year 2024 sales guidance raised to high end of 8-10% range; TMTT guidance raised to $320-340M.","Critical Care spin-off on track; full-year adjusted EPS guidance maintained at $2.70-$2.80."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":1598200000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239512,"accession_number":"0001099800-24-000031","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Edwards Lifesciences Chairman Michael Mussallem to Retire, Nicholas Valeriani to Succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael A. Mussallem will retire as Non-Executive Chairman and director effective May 7, 2024, the date of the annual meeting.","Nicholas J. Valeriani, an independent director, is expected to be appointed as Chairman of the Board.","Martha H. Marsh will not stand for re-election due to reaching retirement age under company guidelines.","The changes were announced on March 26, 2024, in an 8-K filing by Edwards Lifesciences (NYSE: EW)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239511,"accession_number":"0001099800-24-000002","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q4 sales $1.53B (+14% YoY); 2024 guidance reiterated with higher TMTT outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 sales $1.53B (+14% reported, +13% constant currency); TAVR $979M (+13%).","Q4 GAAP EPS $0.61, adjusted EPS $0.64; full-year 2023 EPS $2.30 (GAAP), $2.51 adjusted.","TMTT sales $56M in Q4, $198M full year (+65% constant currency); EVOQUE received FDA approval for tricuspid regurgitation.","2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80; Q1 sales $1.53-1.61B.","Repurchased $444M in Q4, $867M in 2023; $1B remaining authorization; cash $1.6B, debt $600M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":6004800000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257043,"accession_number":"0001099800-23-000042","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Edwards plans tax-free spin-off of Critical Care, issues 2024 sales guidance $6.3-6.6B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Edwards plans tax-free spin-off of Critical Care at end of 2024; Katie Szyman to be CEO of new company.","2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80.","2024 TAVR sales $4.0-4.3B (8-10% growth); TMTT sales $280-320M.","Board authorized $1B additional share repurchase authorization.","Clinical milestones: PROGRESS enrollment complete early 2024, EARLY TAVR data at TCT 2024, EVOQUE US approval mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257042,"accession_number":"0001099800-23-000037","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q3 sales $1.48B (+12%), EPS $0.63; TAVR grows 11%; guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1.48B (+12% reported, +11% constant currency); GAAP EPS $0.63, adjusted EPS $0.59.","TAVR sales $961M (+11%); TMTT sales $52M on PASCAL Precision adoption; Surgical $247M (+12%).","Adjusted gross margin 76.4% vs 81.0% a year ago on FX headwinds; FY2023 guidance reaffirmed (10-13% CC sales growth, adj. EPS $2.50-$2.60).","Regulatory milestones: EVOQUE CE Mark (first transfemoral tricuspid replacement), PASCAL Precision approved in Japan, SAPIEN M3 pivotal trial enrollment completed.","Free cash flow $356M; $174M share repurchased in Q3; cash & short-term investments $1.9B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":4470700000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274375,"accession_number":"0001099800-23-000032","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q2 sales $1.53B (+11% YoY); adj EPS $0.66; raises FY23 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $1.53B (+11%/+12% constant currency); GAAP EPS $0.50 (incl. IP charge), adjusted EPS $0.66.","TAVR sales $992M (+9%/+10% constant currency); TMTT $48M; Surgical $256M; Critical Care $235M.","Raised FY2023 sales guide to $5.9-$6.1B (prior $5.6-$6.0B), constant currency growth 10-13%.","Adjusted EPS guide raised to $2.50-$2.60 (prior $2.48-$2.60); Q3 guide $1.44-$1.52B sales, $0.55-$0.61 adj EPS.","Adjusted gross margin 77.7% (vs 80.5% YoY); $300M IP payment; cash $1.5B, debt $600M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":2989800000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291627,"accession_number":"0001193125-23-144564","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Edwards Lifesciences raises CEO Zovighian's base salary to $1.05M; shareholders approve officer exculpation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased Bernard J. Zovighian's base salary to $1,050,000 and annual incentive target to $1,470,000, effective May 11, 2023.","Stockholders approved amendment to certificate of incorporation to provide officer exculpation under Delaware law; filed May 12, 2023.","All nine director nominees elected; say-on-pay advisory vote approved with 438.1M for; one-year frequency chosen for future votes.","Shareholder proposal for independent board chairman policy rejected with 371M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291626,"accession_number":"0001099800-23-000019","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q1 sales $1.46B (+9% YoY), adj EPS $0.62; raises FY guidance, CEO to retire","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $0.56; adjusted EPS $0.62 vs prior guidance implied range.","TAVR sales $948M (+8% YoY, +11% cc); TMTT $42M; Surgical $248M; Critical Care $222M.","Full-year sales guidance raised to high end of $5.6-6.0B; adj EPS guidance raised to $2.48-2.60.","Repurchased ~$250M stock in Q1; free cash flow $253M.","CEO Michael Mussallem retiring next month; Bernard Zovighian to succeed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1459600000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312401,"accession_number":"0001193125-23-043538","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Edwards Lifesciences amends bylaws to adopt universal proxy rules and update advance notice provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bylaws amended to incorporate Rule 14a-19 universal proxy requirements for director nominations.","Stockholders must provide evidence of compliance with universal proxy rules, including soliciting at least 67% voting power.","Advance notice provisions updated with additional disclosure requirements for nominees and proposing stockholders.","Company may require proposed nominees to submit to interviews with the Board or a committee.","Other technical and conforming changes to align with recent amendments to Delaware General Corporation Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312400,"accession_number":"0001099800-23-000003","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q4 sales up 1% to $1.35B; adjusted EPS grows 25% to $0.64","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 TAVR sales flat at $868M; constant-currency growth 5%; U.S. procedures rose mid-single digits.","Full-year 2022 sales $5.38B (+3%); adjusted EPS $2.48 (+12% YoY).","Repurchased $1.7B of stock in 2022; $900M remaining under authorization.","Q4 adjusted gross margin improved to 81.0% from 76.8% a year ago.","Reiterated 2023 outlook: sales growth 9-12% ($5.6-$6.0B); adjusted EPS $2.45-$2.60."],"consensus_eps_estimate":null,"consensus_eps_actual":2.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":5382400000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330945,"accession_number":"0001193125-22-301136","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Edwards Lifesciences CEO Mike Mussallem retiring May 2023; Bernard Zovighian to become CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Mussallem (70) to retire at May 11, 2023 annual meeting; will become non-executive chairman.","Bernard Zovighian named President effective Jan 1, 2023, then CEO on May 11, 2023.","Larry Wood expands to corporate VP and group president for TAVR and Surgical Structural Heart.","Daveen Chopra to succeed Zovighian as head of Transcatheter Mitral & Tricuspid Therapies (TMTT).","Zovighian base salary increased to $800k, incentive target $800k; Wood to $750k each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330944,"accession_number":"0001193125-22-274553","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Edwards Lifesciences announces $750M accelerated share repurchase, initial ~8M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$750M ASR executed; initial delivery of ~8M shares, remainder based on VWAP over term.","Total 2022 repurchases exceed $1.7 billion.","Approximately $900 million remains in board-authorized repurchase plan.","Repurchase funded with existing cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330943,"accession_number":"0001099800-22-000023","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q3 sales $1.32B; adjusted EPS $0.61 (up 13% YoY); cuts FY22 adjusted EPS guidance to $2.40-$2.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.55, adjusted EPS $0.61; $0.07/share charge from discontinuing HARPOON surgical mitral repair.","TAVR sales $862M (+1% reported, +6% cc); TMTT sales $30M; U.S. procedures grew mid-single digits YoY.","2022 adjusted EPS guidance revised to $2.40-$2.50 from prior $2.50-$2.65 range; total sales now expected at low end of $5.35-$5.55B.","Received U.S. FDA and CE Mark for PASCAL Precision; U.S. FDA approval for SAPIEN 3 Ultra RESILIA valve.","Q3 free cash flow $250M; cash and investments $1.7B as of Sept. 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":4034100000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348497,"accession_number":"0001099800-22-000016","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q2 sales flat at $1.37B; lowers FY2022 outlook on FX, staffing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $1.37B flat YoY; underlying growth 5%. GAAP EPS $0.65, adjusted EPS $0.63.","TAVR sales $907M (+1% reported, +5% underlying); TMTT $28M; Surgical $229M; Critical Care $211M.","Full-year sales guidance lowered to $5.35-$5.55B; adjusted EPS guided to low end of $2.50-$2.65.","Q2 share repurchases of $355M; Board approved new authorization with $1.9B remaining.","Adjusted gross margin improved to 80.5% from 75.9%, helped by FX hedge gains."],"consensus_eps_estimate":null,"consensus_eps_actual":1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":2715100000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348496,"accession_number":"0001193125-22-199173","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2022-07-21T23:59:59+00:00","items":["1.01","2.03","1.02","9.01"],"status":"ready","headline":"Edwards Lifesciences enters new $750M five-year revolving credit facility, replaces 2018 agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $750M unsecured multi-currency revolving credit facility matures July 15, 2027.","Pricing improved vs. 2018 facility; margin tied to leverage ratio or debt ratings.","Facility includes options for increase up to $250M additional and multicurrency sub-limits.","No amounts drawn as of July 15, 2022; proceeds for general corporate purposes and refinancing.","Terminated the existing 2018 credit agreement on same date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365193,"accession_number":"0001193125-22-140622","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Edwards Lifesciences holds 2022 annual meeting; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected, including Kieran T. Gallahue, Leslie H. Heisz, Paul A. LaViolette, and others.","Say-on-pay advisory proposal approved with 450M for, 49.9M against, 1.5M abstain.","Ratification of PwC as auditor for FY2022 approved with 503M for, 31.9M against.","Shareholder proposal to reduce special meeting ownership threshold failed with 181.6M for, 315M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365192,"accession_number":"0001099800-22-000007","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q1 sales $1.34B (+13% underlying), adjusted EPS $0.60; TAVR up 14% underlying","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $1.34B, up 10% reported (13% underlying); adjusted EPS $0.60.","TAVR sales $881M (+11% reported, +14% underlying); global TAVR opportunity seen doubling to $10B by 2028.","Full-year 2022 guidance: sales $5.5-6.0B, adjusted EPS $2.50-$2.65; Q2 sales $1.36-1.44B.","MITRIS RESILIA valve for mitral position received US FDA approval and launched commercially.","Repurchased ~$400M stock in Q1; free cash flow $221M; cash $1.5B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":1341200000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384786,"accession_number":"0001099800-22-000002","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2022-01-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q4 sales $1.33B (+12% YoY); adjusted EPS $0.51; guides FY22 sales $5.5-6.0B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $1.33B, up 12% (13% underlying); TAVR sales $872M (+12%); TMTT $25M.","Q4 GAAP EPS $0.53; adjusted EPS $0.51.","Full year 2021 sales $5.2B (+19%); adjusted EPS $2.22 (+19% YoY).","FY22 guidance: sales $5.5-6.0B (low double-digit growth); adjusted EPS $2.50-$2.65; Q1 sales $1.27-1.35B.","Completed enrollment of CLASP IID and EARLY TAVR trials; FDA approved SAPIEN 3 with Alterra."],"consensus_eps_estimate":null,"consensus_eps_actual":2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":5232500000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402668,"accession_number":"0001099800-21-000024","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2021-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Lifesciences Q3 sales up 15% to $1.3B; EPS $0.54; guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $1.3B, up 15% reported (14% underlying); TAVR sales $858M, up 15% (14% underlying).","Adjusted EPS $0.54; full-year 2021 sales guidance unchanged at $5.2-$5.4B; adjusted EPS guided to high end of $2.07-$2.27.","TMTT sales $22M; company on track for U.S. approval of PASCAL platform for degenerative mitral regurgitation late 2022.","Free cash flow $471M in Q3, $1.1B YTD; cash and investments $3.1B, total debt $596M.","Q4 2021 guidance: sales $1.30-$1.38B, TAVR $850-$910M, adjusted EPS $0.53-$0.59."],"consensus_eps_estimate":null,"consensus_eps_actual":1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":3902800000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421587,"accession_number":"0001099800-21-000020","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Edwards Q2 sales $1.4B (+49% YoY); raises FY2021 sales & adjusted EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2021 sales $1.4B, up 49% reported (44% underlying); diluted EPS $0.78, adjusted EPS $0.64.","TAVR sales $902M (+52% reported, +48% underlying); FY2021 TAVR growth guidance raised to ~20%.","Full-year 2021 sales guidance raised to $5.2–$5.4B (from $4.9–$5.3B); adjusted EPS guided to high end of $2.07–$2.27.","Q3 2021 guidance: sales $1.29–$1.37B, adjusted EPS $0.50–$0.56.","Free cash flow $457M; cash $2.6B; repurchased 1.3M shares for $112M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":2592600000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421586,"accession_number":"0001193125-21-216533","cik":1099800,"company_name":"Edwards Lifesciences Corp","ticker":"EW","form_type":"8-K","filed_at":"2021-07-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Edwards Lifesciences amends bylaws to allow virtual meetings and exclusive federal forum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted amended bylaws on July 15, 2021, authorizing virtual-only stockholder meetings and electronic delivery of notices.","Advance notice provisions now limit director nominees to the number of seats up for election and require nominator to be a stockholder of record.","Exclusive forum clause designates federal district courts for claims arising under the Securities Act of 1933.","Electronic proxies, written consents, and electronic signatures are explicitly permitted in accordance with Delaware law updates.","Stock certificates may now be signed by any two authorized officers, removing prior specified officer combinations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":49812457465.36543,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}